Bruce Lyday has been a researcher in the fields of virology, immunology, and oncology for over 30 years. He developed a cancer immunotherapy that combines an oncolytic, immune stimulating virus, Dengue-1 #4AZ5, developed by the US Army as a vaccine, in combination with tumor peptide-pulsed dendritic cells. When COVID restricted inpatient trials, he came up with a unique Prime-Boost vaccine for SARS-2. This approach uses a Alphavirus vector carrying a SARS-2 transgene target with an intranasal boost of several variant SARS-2 Spike proteins in a balanced TH1/TH2 cytokine adjuvant. The approach is designed to overcome several obstacles faced with the current market leading mRNA technology: concerns over cardiac injury, lack of mucosal immunity to prevent infection, and Immune Imprinting.